SCHEMBL6300343

SCHEMBL6300343

COC(=O)c1cc(C)c2nc(C)n(Cc3ccc(-c4ccccc4)cc3Cl)c2n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PIK3CB P42338 2/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
DCTPP1 Q9H773 1/20 0.36
PPARG P37231 1/20 0.36
MME P08473 1/20 0.36
ACE P12821 1/20 0.36
AR P10275 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6299864 0.90 PIK3CB (0.41) ALDH1A1MAPTSMN1; SMN2PIK3CBMME
SCHEMBL6300588 0.87 MEN1 (0.38) MEN1NPC1RAB9AKMT2AALDH1A1
SCHEMBL6503451 0.86 HPGD (0.44) MEN1RAB9AKMT2AALDH1A1KDM4E
SCHEMBL6298702 0.86 NR4A2 (0.38) MEN1NPC1RAB9AKMT2AALDH1A1
SCHEMBL6491019 0.86 DCTPP1 (0.38) MEN1NPC1RAB9AKMT2AALDH1A1
SCHEMBL6299688 0.85 ALDH1A1 (0.44) MEN1NPC1RAB9AKMT2AALDH1A1
SCHEMBL6299034 0.85 MEN1 (0.35) MEN1NPC1RAB9AKMT2AALDH1A1
SCHEMBL6299204 0.85 DCTPP1 (0.41) MEN1NPC1RAB9AKMT2APIK3CB
SCHEMBL6299229 0.85 MAPT (0.39) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL6299102 0.85 DCTPP1 (0.38) MEN1NPC1RAB9AKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911469-B2 Sulfonamide compounds and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-28 US disclosed
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-16 US disclosed
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-07-25 US disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity PDE2A, PDE3A, PDE12 MEN1 4378/4885NPC1 4449/4885RAB9A 2759/4885
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications PDE2A, PDE3A, PYGM MEN1 4834/4885NPC1 4845/4885RAB9A 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.